DaVita Q2 Revenue Rises, Net Income Drops

DaVita Inc. reported a 6.1% year-on-year increase in Q2 2025 revenues to $3.38 billion, exceeding analyst forecasts, with adjusted earnings per share at $2.95. The company's U.S. dialysis and ancillary services accounted for most of the revenue growth, while added revenue came from incorporating phosphate binders into payment bundles. Despite steady demand and new center openings, net income for the first half of 2025 fell 16.3% from a year earlier, primarily due to higher interest expenses and cybersecurity-related costs. Operating challenges included elevated administrative expenses and disruptions from a ransomware attack. DaVita maintained its full-year adjusted EPS guidance and emphasized ongoing investment in patient care. Company shares have lagged the broader market so far this year as investors watch for future earnings signals.